Community Search
Come Meet Us: Latest News

FDA Approves Expanded Label for AZILECT for Treatment Across All Stages of Parkinson's Disease

Tuesday, June 10, 2014   (0 Comments)
Share |
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT(R) (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs). The new indication reflects that AZILECT(R) can be used alone or in combination with other Parkinson's disease (PD) medications. The approval reinforces the growing clinical evidence demonstrating the benefit of AZILECT(R) across all stages of PD.

Read full article:

Membership Management Software Powered by YourMembership  ::  Legal